Hikma vs. Cipla: Naloxone Nasal Spray Patent Dispute Dismissed After 475 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Hikma Pharmaceuticals USA, Inc. v. Cipla Limited |
| Case Number | 1:23-cv-01157 |
| Court | U.S. District Court, District of Delaware |
| Duration | Oct 2023 – Jan 2025 1 year 3 months |
| Outcome | Defendant Win – Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Cipla’s proposed generic naloxone hydrochloride nasal spray product |
Case Overview
In a case that intersected opioid crisis response technology with high-stakes pharmaceutical patent litigation, Hikma Pharmaceuticals USA, Inc. filed suit against Cipla Limited in the Delaware District Court on October 13, 2023, asserting infringement of five patents covering its Kloxxado® naloxone hydrochloride nasal spray (8 mg/spray). After 475 days of litigation, the parties reached a joint resolution — filing a consent order of dismissal without prejudice on January 30, 2025.
The Parties
⚖️ Plaintiff
U.S. subsidiary of a multinational specialty pharmaceutical company, marketer of Kloxxado® naloxone nasal spray.
🛡️ Defendant
Global generics pharmaceutical company with substantial U.S. operations, accused of infringing Hikma’s patents covering naloxone nasal spray.
Patents at Issue
This case involved five U.S. patents covering Hikma’s Kloxxado® naloxone hydrochloride nasal spray formulation and delivery technology, forming a layered patent portfolio:
- • US11628139B2 — Naloxone hydrochloride nasal spray formulations
- • US11135155B2 — Delivery mechanisms for opioid reversal drugs
- • US11617713B2 — Related pharmaceutical methods and compositions
- • US10722510B2 — Formulations of naloxone for nasal administration
- • US10973814B2 — Pharmaceutical compositions for nasal drug delivery
Developing a similar drug product?
Check if your naloxone formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On January 30, 2025, the Delaware District Court entered a Consent Order of Dismissal Without Prejudice upon the joint application of Hikma Pharmaceuticals USA, Inc. and Cipla Limited (inclusive of Cipla USA Inc.). No damages were awarded, and no injunctive relief was imposed. The specific terms of any underlying settlement or licensing agreement were not disclosed in the public record.
Key Legal Issues
A dismissal without prejudice is not a victory for either party in the traditional sense — but it is far from neutral. Critically, it preserves Hikma’s right to re-file infringement claims against Cipla on the same patents if circumstances change, such as Cipla launching a product, modifying its ANDA, or a negotiated agreement lapsing.
Because no merits ruling was issued, this case does not establish binding precedent on naloxone formulation patent claims. However, it reinforces several important patterns in pharmaceutical patent litigation:
- Portfolio depth matters: Asserting multiple related patents significantly complicates an accused infringer’s invalidity and non-infringement analysis.
- Pre-trial resolution is common: The majority of Hatch-Waxman cases resolve before trial, often through consent orders.
- Delaware remains the dominant venue for pharmaceutical patent disputes, offering predictability and judicial familiarity with complex IP issues.
Filing a drug patent?
Learn from this case. Use AI to draft stronger claims for pharmaceutical formulations.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the competitive naloxone nasal spray market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in naloxone delivery technology
- See which companies are active in opioid reversal patents
- Understand claim construction patterns for drug delivery
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own naloxone formulation or drug delivery product.
- Input your product description or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Naloxone nasal spray formulations & delivery
5 Asserted Patents
In this specific dispute
Strategic Settlement
Dismissal without prejudice allows flexibility
✅ Key Takeaways
For Patent Attorneys & Litigators
Dismissal without prejudice preserves re-filing rights, offering strategic flexibility in pharmaceutical litigation.
Search related case law →Asserting multi-layered patent portfolios for drug products increases litigation complexity and settlement leverage.
Explore precedents →For R&D Leaders
Conduct comprehensive FTO analysis for naloxone formulations early, considering dense patent landscapes for delivery mechanisms.
Start FTO analysis for my product →Evaluate product design-around opportunities early in ANDA development, particularly for complex drug delivery formats.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.